Table 2.
Potential targets, targeted therapies and open clinical trials for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphomas (PTCL).
| Target | Targeted Therapy | Current Clinical Trials | Eligible Diseases |
|---|---|---|---|
| CD1a | CD1a CAR-T | N/A | Cortical T-ALL |
| CD3 | CD3 NK CAR-T | N/A | T-ALL |
| CD4 | CD4 CAR-T | NCT03829540 | CD4 + T-ALL, CD4 + PTCL |
| CD5 | CD5 CAR-T | NCT03081910 | CD5 + T-ALL, CD5 + PTCL |
| CD7 | CD7 CAR-T | NCT03690011 | T-ALL, CD7+ PTCL |
| CD25 | Basiliximab | N/A | N/A |
| CD30 | Brentuximab CD30 CAR-T |
NCT01979536
NCT02729961 NCT02917083 NCT03383965 NCT04008394 |
ALCL ALCL CD30+ PTCL ALCL CD30+ PTCL |
| CD38 | Daratumumab Isatuximab |
NCT03384654
NCT03860844 |
T-ALL T-ALL |
| CD52 | Alemtuzumab | N/A | N/A |
| CD194 | Mogamulizumab CD194/30 CAR-T | N/A NCT03602157 |
N/A |
| hTERT | hTERT directed CAR-T | N/A | N/A |
| IL7 R-a | Antibodies 4A10, 2B8 ADC B12-MMAE | N/A | N/A |
CAR-T: chimeric antigen receptor T-cell; NK: natural killer; ADC: antibody-drug conjugate.; T-ALL: T-cell Acute Lymphoblastic Leukemia; PTCL: Peripheral T-cell Lymphoma.